Objectives: Endoscopic dacryocystorhinostomy (Endo DCR) is a standard treatment for nasolacrimal duct obstruction, though outcomes may be compromised by intraoperative bleeding and postoperative inflammation. This study evaluated the clinical efficacy of Novacol Fibrillar®, a collagen-based absorbable hemostatic agent, in Endo DCR.
Methods: A retrospective review was conducted on 357 patients who underwent Endo DCR from January 2018 to September 2024. The Novacol group (n = 168) received Novacol packing, while the Nasopore group (n = 189) received Nasopore. Primary outcomes included anatomical and functional success, operative time, and intraoperative bleeding. Secondary outcomes included granulation, infection, epistaxis, postnasal drip, and revision surgery within 3 months.
Results: The Novacol group showed higher anatomical (94.6% vs 85.2%, P = .039) and functional (93.5% vs 84.1%, P = .023) success. Intraoperative bleeding was lower (9.5 vs 12.4 gauzes, P = .022), as were rates of granulation (9.5% vs 24.3%, P = .009), epistaxis (5.4% vs 21.7%, P = .028), postnasal drip (6.5% vs 23.3%, P = .032), and revision surgery (2.4% vs 16.4%, P = .041). Infection rates were not significantly different (P = .083).
Conclusions: Novacol Fibrillar improved surgical outcomes and reduced complications in Endo DCR, supporting its use as an effective hemostatic packing material.
扫码关注我们
求助内容:
应助结果提醒方式:
